Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and turnouts

R. E. Schwab, S. Froidevaux, S. Paku, M. Tejeda, B. Szende, Á Pap, C. Beglinger, A. N. Eberle, G. Kéri

Research output: Contribution to journalArticle

15 Citations (Scopus)


Background: TT-232, a somatostatin analogue, induces apoptosis in various tumours. The aim of our study was to characterise its effect on human melanoma cells and tumours. Materials and Methods: Proliferation of seven melanoma cell lines was tested in vitro with the methylene blue test. D10 and 205 cells were also implanted into CB17-scid mice which received 30-150-750 μg/kg/day of TT-232 or saline. Animals with 205 cells received twice-daily subcutaneous injections whereas animals with D10 cells were treated with osmotic mini-pumps. In addition, TT-232 metabolites were generated with tissue homogenates and tested in vitro. Results: TT-232 strongly inhibited proliferation of all cell lines in vitro and tumour growth in vivo. Two out of 8 animals (30-150 μg/kg) in the 205 model and one out of 8(150 μg/kg) in the D10 model became completely tumour-free at the 11th and 9th day of treatment, respectively. TT-232 was degraded only by liver homogenate whilst its metabolite had no antiproliferative effect in vitro. Conclusions: TT-232 is a promising drug candidate for melanoma.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalAnticancer research
Issue number1 A
Publication statusPublished - Apr 18 2001


  • Experimental therapy
  • Melanoma
  • Metabolism
  • Somatostatin analogue
  • TT-232

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and turnouts'. Together they form a unique fingerprint.

  • Cite this